Likes vs Sharing

who remembers this old commercial…  when you like a post on a blog, FB or twitter all you are doing is letting the company behind the website to collect data about YOU… when you regularly share…then your friends gets the post to hopefully read and hopefully share with their friends.

How many people that there are spread out there on at least a THOUSANDS different FB pages that deal with pain and/or diseases where pain is a significant factor ?

I know that I get and I am sure that many other who post things that should “educate” the chronic pain community … same/similar questions every week. Is this because chronic pain pts and their advocates are spread out over 1000+ different websites, FB and twitter locations ?

Many complain that there is a great deal of unity lacking among those in the chronic pain community.  Maybe that is because they “function” within their own little social circle ?

Progress moving forward for the chronic pain community will be very slow, if the vast majority are sitting with their “engine idling and their transmission in NEUTRAL”

Advocates decry Ohio pharmacy board vote to ban kratom

Advocates decry Ohio pharmacy board vote to ban kratom

https://www.dispatch.com/news/20190308/advocates-decry-ohio-pharmacy-board-vote-to-ban-kratom

A group that advocates for consumer access to the herbal supplement kratom says the State of Ohio Board of Pharmacy erred in approving a proposal to ban the product that has been touted as way to fight the opioid epidemic.

The board on Wednesday voted to approve its proposal to classify the Southeast Asian herb as a Schedule 1 Controlled Substance, which would place it in the same class as heroin, LSD and other illegal drugs. It now faces review by two other government bodies.

The board was not swayed by scientific studies that the association presented refuting U.S. Food and Drug Administration findings, said C.M. Haddow, a public policy fellow at the Virginia-based American Kratom Association. Opposed to bans, the association is lobbying in Ohio and elsewhere for laws that would make the product illegal for minors, require labeling and regulate for quality and purity.

Pharmacy board spokesman Cameron McNamee said staff members scoured medical journals to provide board members with scientific research and also presented them with the research provided by the Kratom Association.

He said regulation instead of a ban could represent a “middle ground,” but “at this point the board feels the science behind it is more of a concern from a public health perspective.”

The leaves of the tropical kratom tree, native to Southeast Asia, contain substances that can have mind-altering effects, according to the National Institute on Drug Abuse at the U.S. Department of Health & Human Services. Haddow said its use increased in the U.S. after soldiers who fought in Vietnam found it reduced fatigue and pain.

The Kratom Association estimates there are 5 million users in the U.S, and say it is sold by a number of retailers in central Ohio.

The herbal supplement is banned in six states and the District of Columbia.

The FDA has reported 44 deaths associated with kratom since 2011, but Haddow said a review by the Kratom Association shows that figure represents global deaths.

At least one of the deaths is being investigated as possible use of pure kratom, and most appear to have resulted from other drugs being mixed with kratom by the manufacturer or from using it with other substances or medications, such as illegal drugs or cough syrup, the National Institute on Drug Abuse says on its website.

Haddow said regulation is necessary to prevent a “Wild West marketplace” in which kratom can be spiked with anything from synthetic materials to heroin.

The pharmacy board vote came two weeks after a study published by the journal Clinical Toxicology showed that reports to U.S. poison-control centers about kratom rose from 13 in 2011 to 682 in 2017. In that period, there were 11 U.S. deaths associated with kratom exposure, including two after exposure to kratom only, according to the study by researchers at Nationwide Children’s Hospital, Northeast Ohio Medical University, the Central Ohio Poison Center and Ohio State University.

The board vote also came two weeks after the Moritz College of Law at Ohio State hosted a panel discussion on kratom. Among panelists were Haddow and Dr. Robert Weber, administrator for pharmacy services at Ohio State’s Wexner Medical Center, who has a far different opinion of the herb than Haddow.

Weber said in a Friday interview that kratom stimulates opiate receptors in the brain, making it similar in action to opioid medications. Overdoses have been documented, he said, and it is important to be careful about how kratom is used by the public.

“This should be considered to be a dangerous substance because of the fact that it has very similar characteristics to opiates,” he said. “To protect the health of the public, I think there needs to be education, and there needs to be regulation.”

Doug Berman, executive director of the Drug Enforcement and Policy Center at the law college, moderated the panel, and he said issues discussed included the effect a ban would have on driving the product to the black market.

“The huge fundamental issue is do we want the government saying ‘we’re unsure about this, therefore we prohibit it until we can be sure it’s safe’?” he said. “Or do we say ‘some people are benefiting from this, even if there is risk, let it be legal until we get proof that it’s more harmful than healthy’?’”

The proposed ban will be sent to the Common Sense Initiative in Gov. Mike DeWine’s office, where it will by analyzed for how it will impact business, said board spokeswoman Ali Simon. If it is accepted there, the ban will move to the legislature’s Joint Committee on Agency Rule Review, which would determine if the ban is within the board’s rule-making authority.

Both reviews will involve public comment periods.

Did anyone notice that in this copy/text that they reference that Kratom is “associated” with some OD deaths… so it MUST BE BANNED… but have anyone noticed that it is not tracked nor made public how many OD”s have ALCOHOL ASSOCIATED WITH THE OD ?

Also never tracked nor made public how many OD’s that there is some sort of MENTAL HEALTH ISSUES associated with the person… diagnosed, undiagnosed and/or just untreated

It is like trying to figure out what a puzzle is going to look like with a lot of pieces still missing

Here is the MOST MORONIC STATEMENT:   The proposed ban will be sent to the Common Sense Initiative in Gov. Mike DeWine’s office, where it will by analyzed for how it will impact business

Forget the hundreds of thousands of people in Ohio that benefit from the use of Kratom… Let’s worry about the loss of SALES TAX and other TAXES that businesses generate and pay to the state

Pt had ingested far more pills than prescribed on the day he died and had taken other drugs that were not prescribed

Kansas doctor sentenced to life in prison for patient death

https://wtop.com/national/2019/03/kansas-doctor-sentenced-to-life-in-prison-for-patient-death/amp/

WICHITA, Kan. (AP) — A Kansas doctor was sentenced to life in prison Friday for unlawfully prescribing medication blamed for an overdose death, the latest prosecution in a government crackdown on physicians amid an opioid epidemic.

Steven R. Henson was immediately taken into custody following sentencing. There was an audible gasp in the packed courtroom when U.S. District Judge J. Thomas Marten pronounced the life sentence. Henson showed no emotion.

A federal jury convicted the 57-year-old Wichita doctor for the 2015 death of Nick McGovern. Prosecutors alleged McGovern, who received prescriptions from Henson, died of an overdose of the anti-anxiety drug alprazolam and methadone, which is used to wean addicts off heroin.

The government presented evidence at trial that Henson wrote prescriptions in return for cash, postdated prescriptions and wrote them without a medical need or legitimate medical exam. Prosecutors said the doctor prescribed opioid medications in amounts likely to lead to addiction.

He also was convicted of conspiracy to distribute prescription drugs outside the course of medical practice, unlawfully distributing various prescription drugs, presenting false patient records to investigators, obstruction of justice and money laundering.

His case is the latest in a string of prosecutions across the nation targeting physicians accused of overprescribing opioids.

“I want this case to send a message to physicians and the health care community,” U.S. Attorney Stephen McAllister said in a news release. “Unlawfully distributing opioids and other controlled substances is a federal crime.”

The National Association of Attorneys General, working under a research grant, found there had been 378 doctors who had been charged or whose cases were resolved by the end of 2016. Of those, U.S. attorneys’ offices charged 249 and state authorities charged 131, its researchers found.

Defense attorney Michael Thompson said his client was disappointed in the sentence and planned to appeal.

“When acting as a physician he always acted with the best interest of patients,” Thompson said.

His attorneys had urged the court to impose the lowest possible sentence, arguing McGovern had ingested far more pills than prescribed on the day he died and had taken other drugs that were not prescribed. They contended Henson did not write a prescription that would have resulted in the death if taken as directed.

In a brief courtroom statement, Henson said he trained hard to become a physician.

“I only had one goal in life as a physician and that is to take excellent care of patients and increase functionality,” he said.

But the judge was unmoved by that statement, telling Henson he put his patient in a position where he had to take those pills in order to get through the day.

“You were exacerbating a problem; you were not treating it,” Marten said.

Several tearful members of the McGovern’s family spoke in court of the impact the death has had on them, telling the court the family deserves to see justice served so this example won’t ever happen to another family.

Some 47,600 Americans died of opioid overdoses in 2017 , according the U.S. Centers for Disease Control and Prevention. Opioid deaths were 13 percent higher compared to 2016, up a notch compared to the nearly 500 percent increase in overdose deaths since 1999. The street drug fentanyl is the top overdose killer now, displacing heroin and pain pills. Prescription painkillers contributed to 14,495 deaths in 2017.

This doctor apparently did not get a trial by jury… just a judge..  Here is a quote from the Prosecutor Prosecutors said the doctor prescribed opioid medications in amounts likely to lead to addiction..ADDICTION IS A MENTAL HEALTH DISEASE

He also stated:  methadone, which is used to wean addicts off heroin..   If a person lives in the state of WASH and is a chronic pain they will ONLY GET METHADONE for their pain – unless allergic to it.

The Defense stated:  McGovern had ingested far more pills than prescribed on the day he died and had taken other drugs that were not prescribed.

This is a non-compliance issues – a PERSONAL CHOICE… how many prescribers have been sent to jail because one or more of their pts DID NOT TAKE THEIR MEDICATION AS DIRECTED and died from complications of their UNTREATED HEALTH ISSUES  ?  HOW ABOUT ZERO !!

Here is a LIE that the media keeps repeating:  Prescription painkillers contributed to 14,495 deaths in 2017  Once “prescription painkillers” are no longer in the possession of the entity/person that has the legal right to possess them (Pharma, wholesaler, Pharmacy, pt prescribed to) they AUTOMATICALLY become an ILLEGAL OPIATE.  Is this a stat that they don’t track or just don’t divulge to the public ?

 

 

Daily Briefing with Dana Perino

Senator introduces bill to end PBM drug rebates in commercial plans

Senator introduces bill to end PBM drug rebates in commercial plans

https://www.fiercehealthcare.com/payer/senator-introduces-bill-to-end-pbm-drug-rebates-commercial-plans

The Trump administration has made moves to eliminate drug rebates in federal payers, and now, thanks to a bill introduced in Congress on Wednesday, such contracts in the commercial sector are also on the chopping block. 

Sen. Mike Braun, R-Ind., introduced the Drug Price Transparency Act alongside two other bills aimed at lowering drug prices. The bill looks much like the Department of Health and Human Services’ plan: prohibit pharmacy benefit managers from receiving rebates from drug companies and instead require that such discounts be passed directly on to consumers. 

Braun also introduced legislation to clear the Food and Drug Administration’s approval backlog and boost transparency. 

“I’m offering solutions to address rising healthcare prices by adding transparency to our drug pricing, clearing the backlog on pending drug applications at the FDA and providing oversight and accountability in the healthcare industry,” Braun said. 

HHS unveiled its plan to nix the rebates in January, and in the proposed rule it said it intended to eliminate anti-kickback protections to rebates negotiated by PBMs and instead offer the protections to point-of-sale discounts. 

HHS Secretary Alex Azar said when the agency’s proposal on the matter was unveiled that he hoped Congress would follow suit to ensure it was extended nationwide. And even if legislators hadn’t acted, the administration expected that its rule would have ripple effects beyond Medicare. 

JC Scott, president of the Pharmaceutical Care Management Association, a PBM trade group, said in a statement that the legislation doesn’t target the true culprit in high drug prices: pharmaceutical companies. 

“The legislation appears to do absolutely nothing to address the root cause of the problem: the high list prices that only the drug manufacturers have the power to set,” Scott said. “Despite drug manufacturers’ rhetoric, their pricing strategies are unrelated to the rebates they negotiate with PBMs.” 

The bill comes on the heels of a House hearing in which executives at some of the largest drug companies backed eliminating drug rebates

HOW TO BUY A ROLEX AT RETAIL

HOW TO BUY A ROLEX AT RETAIL

How to Buy a Rolex at Retail

Buying a Rolex watch at retail has always been somewhat of an event. Back in the good old days, it usually meant that you were celebrating something (even if you were just celebrating yourself). However, buying a Rolex at retail is now considered an occasion simply because it means that you were lucky enough to get a call from your authorized dealer telling you that the wait is finally over and that you can finally purchase the watch that you want. Check more from these fake rolex deals.

People often talk about the dreaded “waitlist” in regards to Rolex watches and their retail availability, but there are a lot of misconceptions about how allocation is actually determined. While it is certainly true that global demand far exceeds supply, buying a Rolex at retail isn’t actually completely impossible – assuming that you are a genuine enthusiast who is interested in owning the watch, rather than someone who is simply interested in flipping it for a quick profit. Nothing in life is certain (especially when it comes to the retail availability of luxury watches), but here’s how to buy a Rolex at retail.

Rolex Daytona Oysterflex Bracelet

LUXURY AND AVAILABILITY

Before we actually get into how to go about buying a Rolex at retail, it might be worth taking a brief moment to discuss the concept of luxury as it pertains to retail availability. I definitely understand where some people are coming from when they say that a luxury purchase should not involve having to cultivate a relationship with your dealer or spend any amount of time on a waiting list.

To a certain degree, I do agree with that sentiment. A luxury purchase is more than just receiving a premium item in exchange for a decent chunk of change. The process itself should feel luxurious, and (at least in my opinion) a “luxury” experience doesn’t involve being told that you need to wait, nor does it involve buying other items so that you can create a purchase history with your retailer.

However, regardless of our personal sentiments about what constitutes a luxury experience, there is an overwhelming global demand for Rolex watches, and not everyone who wants to buy one is going to be able to get one in a timely manner. I think everyone (including the staff members who work at your local retailer or boutique) would prefer if anyone who wanted a Rolex could simply purchase the watch of their choice (after all, selling watches is how they make money). However, the simple fact that global demand far exceeds supply means that there’s a shortage at a retail level, and whether you like it or not, you’re going to need some relationship with your authorized retailer if you want to buy a brand-new Rolex.

Rolex GMT-Master II Batman

THERE ISN’T ACTUALLY A LIST

Now, I hate to be the one to break this to you, but there isn’t actually a Rolex waiting list. When people say they are on the “waitlist” or that they are waiting for their name to come up at their dealer, they really just mean that they are still waiting for their retailer to be able to allocate them a watch.

There isn’t a master list at Rolex’s headquarters in Geneva with all of the names of everyone who has ever asked an authorized dealer for a Rolex. Not only would that be impossible to track and enforce on a global level, but what would it even look like? A giant scroll of golden paper that is locked away behind a green door with your name printed next to the words, “Pepsi GMT-Master II” – absolutely not. That sounds a bit like what Santa Clause does up at the North Pole, which also happens to be pure fantasy.

While the global allocation of watches to its retail network is determined by Rolex, the actual allocation of watches to consumers is often left to the individual retailer. Rolex does have certain policies, guidelines, and rules for its retailers, but Rolex headquarters is not the one who decides whether or not you get your stainless steel Daytona. That being said, it’s also not like the retailers are just sitting on an unlimited number of stainless steel Rolex sports watches and are just being stingy with the distribution of them. They more-or-less receive what Rolex gives them, and have to then decide who actually gets one.

While a first come, first serve policy might seem like it would be the most fair, it would actually be an absolute nightmare. Everyone complains about all of the people who don’t even like watches and only want to buy a Rolex so that they can sell it for a profit (I know, I hate them too). However, if Rolex were to adopt a first come, first serve policy, it would only mean that an even greater percentage of the available watchers would end up in the hands of these people, rather than genuine enthusiasts who actually want to own the watch. It’s easy to be frustrated with Rolex, but the company and all of its retailers (for the most part) are truly trying their best to make everyone happy.

Rolex Sky-Dweller Stainless Steel

DON’T BE AN ENTITLED JERK

Not being an entitled jerk is something that should apply to all aspects of life, and that even includes when it comes time to splurge and buy yourself a luxury timepiece. I completely understand that it can be frustrating to save up for your dream watch and then not be able to purchase it once you finally have the means to buy it. However, it’s important to remember that it is not your retailer’s fault that global demand exceeds supply, so you certainly shouldn’t take out your frustrations on the staff members who work there, and who genuinely would love to sell you the watch of your dreams if only they had one available.

We all know that there are some people out there who don’t often hear the word “no” and they can sometimes turn into truly flagrant trash-humans when they don’t get what they want. Acting like an entitled jerk isn’t a good look for anyone, and it certainly isn’t going to win over the boutique staff and magically get Rolex to start producing more watches.

You haven’t been able to walk into a Rolex boutique and buy the model you want for several years now, and that isn’t likely to change any time soon. Just because you can afford something doesn’t mean that you are free from common courtesy, and it’s important to remember that regardless of whether or not they are able to provide you with what you want in a timely fashion, you and your dealer have the exact same goal: they want to sell you a watch.

Sgt. Robert Rose Jr. (Ret.) on why he filed a $350 million lawsuit against the VA

The US Food and Drug Administration (FDA) Is Requesting Input From The Public On The Re-Scheduling of Cannabis, aka (Marijuana) Delta 9, THC and CBDs. The Comment Period Ends 11:59 14 March 2019

The US Food and Drug Administration (FDA) Is Requesting Input From The Public On The Re-Scheduling of Cannabis, aka (Marijuana) Delta 9, THC and CBDs. The Comment Period Ends 11:59 14 March 2019

http://governmentnewsarticles.com/government_articles/2019/03/the-us-food-and-drug-administration-fda-is-requesting-input-from-the-public-on-the-rescheduling-of-cannabis-aka-marijuana-delta-9-thc-and-cbds-the-comment-period-ends-1159-14-march-2019-461058.htm#.XILeDpBMGyX

Summary

The Food and Drug Administration (FDA or Agency) is providing interested persons with the opportunity to submit comments about the World Health Organization (WHO) recommendations to impose international manufacturing and distributing restrictions, under international treaties, on certain drug substances. The comments received in response to this notice will be considered in preparing the United States’ position on these proposals for a meeting of the United Nations Commission on Narcotic Drugs (CND) in Vienna, Austria, March 18-22, 2019. This notice is issued under the Controlled Substances Act (CSA).

Dates
Submit either electronic or written comments on the notice by March 14, 2019. The short time period for the submission of comments is needed to ensure that the U.S. Department of Health and Human Services (HHS) may, in a timely fashion, carry out the required action and be responsive to the United Nations.

Addresses
You may submit comments as follows. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before March 14, 2019. The https://www.regulations.gov electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of March 14, 2019. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date.”

This notification reflects the recommendation from the 41st WHO Expert Committee for Drug Dependence (ECDD), which met in November 2018. In the Federal Register of October 10, 2018 (83 FR 50938), FDA announced the WHO ECDD review and invited interested persons to submit information for WHO’s consideration.

The following recommendations regarding the review of cannabis and cannabis-related substances are as follows:

Recommendation 5.1: The Committee recommended that Cannabis and Cannabis Resin be deleted from Schedule IV of the 1961 Single Convention on Narcotic Drugs.
Recommendation 5.2.1: The Committee recommended that dronabinol and its stereoisomers (delta- 9-tetrahydrocannabinol) be added to Schedule I of the 1961 Single Convention on Narcotic Drugs.

Recommendation 5.3.1: The Committee recommended that tetrahydrocannabinol (understood to refer to the six isomers currently listed in Schedule I of the 1971 Convention on Psychotropic Substances) be added to Schedule I of the 1961 Single Convention on Narcotic Drugs, subject to the Commission’s adoption of the recommendation to add dronabinol (delta-9-tetrahydrocannabinol) to the 1961 Single Convention on Narcotic Drugs in Schedule I.

Recommendation 5.4: The Committee recommended deleting Extracts and Tinctures of Cannabis from Schedule I of the 1961 Single Convention on Narcotic Drugs.

Recommendation 5.5: The Committee recommended that a footnote be added to Schedule I of the 1961 Single Convention on Narcotic Drugs to read: “Preparations containing predominantly cannabidiol and not more than 0.2 percent of delta-9-tetrahydrocannabinol are not under international control.

Recommendation 5.6: The Committee recommended that preparations containing delta-9-tetrahydrocannabinol (dronabinol), produced either by chemical synthesis or as a preparation of cannabis, that are compounded as pharmaceutical preparations with one or more other ingredients and in such a way that delta-9-tetrahydrocannabinol (dronabinol) cannot be recovered by readily available means or in a yield which would constitute a risk to public health, be added to Schedule III of the 1961 Convention on Narcotic Drugs.
It is now time for ACTION to #ENDtheMADNESS

Here is your opportunity to make a difference. The short timeline is restrictive but we must deal with it. If you want to change it takes action.

Remember;
If You Do NOTHING, NOTHING will Be Done!

stage 4 pancreatic cancer has a < 5% 5 yr survival rate

He has stage 4 pancreatic cancer and this is the insanity they put him through here !!! As someone called the police claiming to have “Smelt” Marijuana in his hospital room, He didn’t have any marijuana and had taken THC oil in a capsule while outside. And his doctors were aware of it

Nolan’s Tribe of Warriors Against Cancer

stage 4 pancreatic cancer has a < 5% 5 yr survival rate

More than 1,000 accidental drug intoxication deaths in Connecticut in 2018

More than 1,000 accidental drug intoxication deaths in Connecticut in 2018

https://www.wtnh.com/news/health/more-than-1-000-accidental-drug-intoxication-deaths-in-connecticut-in-2018/1830702955

(WTNH) – More than 1,000 people died from accidental drug intoxication in 2018.

This statistic comes from the Office of the Chief Medical Examiner.

According to the office, 948 of the 1017 deaths involved an opioid, while 760 involved fentanyl.

The total number of deaths marks a small drop from 2017, when 1,038 people from Connecticut died from accidental drug intoxication.

However, it is still a sharp increase from 2012 when that number was 357.

Below is a town-by-town list of accidental opioid overdose deaths in the state for 2018 using data from the  Office of the Chief Medical Examiner.

City or town Number of people who died from accidental opioid overdose in city or town
Andover N/A
Ansonia 3
Ashford 1
Avon N/A
Barkhamsted N/A
Beacon Falls 1
Berlin 1
Bethany N/A
Bethel 2
Bethlehem 1
Bloomfield 2
Bolton 1
Bozrah N/A
Branford 9
Bridgeport 58
Bridgewater N/A
Bristol 26
Brookfield N/A
Brooklyn N/A
Burlington 2
Canaan N/A
Canterbury 1
Canton 2
Chaplin N/A
Cheshire 1
Chester 1
Clinton 6
Colchester 4
Colebrook N/A
Columbia 1
Cornwall N/A
Coventry N/A
Cromwell 2
Danbury 18
Darien N/A
Deep River N/A
Derby 10
Durham 1
East Granby N/A
East Haddam N/A
East Hampton 1
East Hartford 17
East Haven 4
East Lyme N/A
East Windsor 2
Eastford 2
Easton N/A
Ellington 2
Enfield 11
Essex 2
Fairfield N/A
Farmington 3
Franklin N/A
Glastonbury 2
Goshen 1
Granby N/A
Greenwich 2
Griswold 1
Groton 9
Guilford 1
Haddam N/A
Hamden 8
Hampton N/A
Hartford 128
Hartland N/A
Harwinton N/A
Hebron 1
Kent N/A
Killingly 1
Killingworth N/A
Lebanon 1
Ledyard 1
Lisbon 1
Litchfield 1
Lyme N/A
Madison 1
Manchester 23
Mansfield 1
Marlborough 3
Meriden 22
Middlebury 3
Middlefield N/A
Middletown 17
Milford 11
Monroe 2
Montville N/A
Morris N/A
Naugatuck 7
New Britain 52
New Canaan 1
New Fairfield N/A
New Hartford 2
New Haven 69
New London 22
New Milford 5
Newington 2
Newtown 1
Norfolk 1
North Branford N/A
North Canaan N/A
North Haven 2
North Stonington N/A
Norwalk 10
Norwich 18
Old Lyme 2
Old Saybrook 2
Orange N/A
Oxford N/A
Plainfield 3
Plainville 2
Plymouth 1
Pomfret N/A
Portland 4
Preston N/A
Prospect N/A
Putnam 5
Redding 1
Ridgefield 1
Rocky Hill 2
Roxbury N/A
Salem 1
Salisbury N/A
Scotland N/A
Seymour 4
Sharon 1
Shelton N/A
Sherman N/A
Simsbury N/A
Somers N/A
South Windsor N/A
Southbury 1
Southington 4
Sprague N/A
Stafford 1
Stamford 13
Sterling 2
Stonington N/A
Stratford 11
Suffield 1
Thomaston 2
Thompson N/A
Tolland 3
Torrington 26
Trumbull 1
Union N/A
Vernon 10
Volluntown N/A
Wallingford 4
Warren N/A
Washington N/A
Waterbury 77
Waterford 1
Watertown 8
West Hartford 7
West Haven 5
Westbrook 2
Weston 1
Westport 1
Wethersfield 5
Willington 1
Wilton N/A
Winchester N/A
Windham N/A
Windsor Locks 2
Wolcott 1
Woodbridge N/A
Woodbury N/A
Woodstock 1